MTHFR and attention deficit-hyperactivity disorder: Cognitive deficits are typically attributed to chemotherapy with methotrexate which inhibits folate pathway enzymes, and the A1298C variant in MTHFR is implied to associate with ADHD risk in 11 cases among 48 ALL patients [42].